INTEGRA LIFESCIENCES HOLDINGS CORP Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $64.90 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-21.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2020-02-21
- INTEGRA LIFESCIENCES HOLDINGS CORP effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2019 was $64.90M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2019-12-31 | $64.90M 10-K · filed 2020-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |